NTR enters the final stretch of August with an unusual alignment: insiders accumulating shares through a multi-month buying programme, short sellers retreating sharply, and the borrow market so loose it barely registers as a constraint.
The clearest thread running through the data is the persistence of insider buying. The CFO, Mark Thompson, has been purchasing shares repeatedly since late May — seven separate transactions totalling well over CAD 100,000 at prices ranging from C$90 to C$96. The Chief Legal Officer, Noralee Bradley, has matched that cadence with five purchases of her own. Neither is deploying transformational capital in any single trade, but the frequency and consistency of the pattern across two senior executives is harder to dismiss than a one-off opportunistic purchase. Net insider buying across the past 90 days amounts to 2,662 shares worth roughly USD 172,000 — small in absolute dollar terms for a company of this size, but telling in its regularity.
The positioning picture reinforces the de-risked tone. Short interest has been cut nearly in half over the past month, falling from roughly 3.7 million shares to 2.3 million — now just 0.48% of the free float. That is a negligible level. Short sellers are not a meaningful force on this name at present, and the borrow market confirms it: availability is extraordinarily loose at over 5,500% of short interest, meaning there are more than 55 shares available to lend for every one currently borrowed. Cost to borrow has dropped to 0.34%, close to its lowest level in the 30-day window. There is simply no squeeze pressure, no squeeze risk, and no sign of new bearish conviction building in the lending market. The ORTEX short score of 26.8 — sitting in the 88th percentile for low short-score rank — flags the same story: this stock ranks among the least shorted in its universe.
The Street view carries a note of caution. Analyst data on file is stale by several years and cannot be used as a current reference. What the factor scores do show is worth noting: earnings momentum is weak, with the 30-day EPS momentum ranking in just the 11th percentile and the 90-day reading in the 15th. Forward earnings estimates have been drifting lower, placing NTR in the 14th percentile for 12-month forward EPS year-on-year growth. The valuation multiples offer some offset — a P/E of 13.7x and EV/EBITDA of 7.1x are not stretched, and both have expanded modestly over the past month as the stock has recovered. The dividend score ranks in the 91st percentile, reflecting NTR's established payout history, though the most recent dividend data in the system predates 2023 and should not be relied upon for current yield calculations. The stock itself is up 4.4% on the week and 4.7% over the past month, trading at C$100.68.
Among close peers, the week's moves were broadly supportive of the fertilizer complex. CF gained 6.3% over the same period. YAR (Yara International) added 8.9%. German peer SDF rose 9.6%. Nutrien's 4.4% weekly gain trails all three, though it follows a stronger prior base. DOW and LYB — less pure-play fertilizer comparisons — both fell on the week, underlining that the chemical sector's performance is fractured along product-line boundaries right now.
What to watch next is whether the November 5 earnings print — the next scheduled event — begins to attract fresh positioning activity or prompts any break in the insiders' steady accumulation pattern. For now, the lending data and short interest suggest very little adversarial pressure on the name, while the buying from inside the building has been quiet but remarkably consistent.
See the live data behind this article on ORTEX.
Open NTR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
